For General Information, page-348

If you had read the recent article written by Corporate Connect on the 29 March 2022....

Title: "Biopharmas Hit, but Buying Opportunities Created"

"Many of the compounds spun-out or sold by the larger companies during the restructuring period that haven’t failed key trials should be starting to reach a stage of development where they will become attractive to the larger biopharmaceutical companies at the right price and under their more stringent rules for progressing drug candidates, which, of course will also apply drug candidates/companies they are looking to acquire.......
Acquiring stock after an event, however, may be a risky move if others are of the same opinion and the price or prices spike. As such, a dollar-cost averaging approach may be a more prudent method of taking a stake in a company or fund. Yes, you may pay a bit extra, but you will certainly be there when things start to really move.

This is exactly what they're mentioned in the news: Sector Watch: Healthcare - M&A fever on the cards?
https://www.finnewsnetwork.com.au/archives/finance_news_network381588.html

"So what does this means?
If this is the start of the biotech M&A fever and there are more deals on the table, it is likely that the value of each one could be higher. It then sparks the opportunity for larger biotech companies to search for undervalued ones."